Associations Between Serum Bone Biomarkers in Early Breast Cancer and Development of Bone Metastasis: Results From the AZURE (BIG01/04) Trial,Journal of the National Cancer Institute

当前位置： X-MOL 学术 › J. Natl. Cancer Inst. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Associations Between Serum Bone Biomarkers in Early Breast Cancer and Development of Bone Metastasis: Results From the AZURE (BIG01/04) Trial
Journal of the National Cancer Institute ( IF 9.9 ) Pub Date : 2018-02-07 , DOI: 10.1093/jnci/djx280
Janet Brown _{1,

2} , Emma Rathbone _{1,

2,

3} , Samantha Hinsley ₄ , Walter Gregory ₄ , Fatma Gossiel ₅ , Helen Marshall ₄ , Roger Burkinshaw ₁ , Helen Shulver ₁ , Hasina Thandar ₆ , Gianfilippo Bertelli ₇ , Keane Maccon ₈ , Angela Bowman ₉ , Andrew Hanby ₂ , Richard Bell ₁₀ , David Cameron ₉ , Robert Coleman ₁

Affiliation

Adjuvant therapies can prevent/delay bone metastasis development in breast cancer. We investigated whether serum bone turnover markers in early disease have clinical utility in identifying patients with a high risk of developing bone metastasis.

中文翻译：